Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
| Autor: | Stein Kvaløy, L. Sandvik, Peter Meyer, Jens Hammerstrøm, Tove Skjelbakken, A. K. Lehmann, Lorentz Brinch, Yngvar Fløisand, Ernst Arne Høiby, T. Fladhagen, E. Nyquist, Dag Torfoss, Fredrik Schjesvold, Harald Holte, J. Dalgaard |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male Lymphoma Antibiotics Benzylpenicillin law.invention 0302 clinical medicine Randomized controlled trial law polycyclic compounds Clinical endpoint 030212 general & internal medicine Prospective Studies Leukemia Norway Aminoglycoside Penicillin G General Medicine Bacterial Infections Middle Aged Anti-Bacterial Agents Infectious Diseases Treatment Outcome Female medicine.drug Microbiology (medical) Adult medicine.medical_specialty Neutropenia Adolescent medicine.drug_class 030106 microbiology Meropenem 03 medical and health sciences Young Adult Internal medicine medicine Humans Mortality Aged business.industry biochemical phenomena metabolism and nutrition medicine.disease Surgery Aminoglycosides Thienamycins business Febrile neutropenia |
| Zdroj: | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 23(3) |
| ISSN: | 1469-0691 |
| Popis: | In Norway, initial treatment of febrile neutropenia (FN) has traditionally been benzylpenicillin plus an aminoglycoside. Internationally, FN is often treated with a broad-spectrum β-lactam antibiotic. We aimed to compare these two regimens in a prospective, randomized, trial in patients with lymphoma or leukaemia with an expected period of neutropenia ≥7 days, and a suspected bacterial infection.Adult neutropenic patients with lymphoma or leukaemia, and a suspected bacterial infection, were randomized for treatment with benzylpenicillin plus an aminoglycoside or meropenem. The primary endpoint was clinical success, defined as no modification of antibiotics and clinical stability 72 h after randomization.Among 322 randomized patients, 297 proved evaluable for analyses. Fifty-nine per cent (95% CI 51%-66%), (87/148) of the patients given benzylpenicillin plus an aminoglycoside were clinically stable, and had no antibiotic modifications 72 h after randomization, compared with 82% (95% CI 75%-87%), (122/149) of the patients given meropenem (p0.001). When the antibiotic therapy was stopped, 24% (95% CI 18%-32%), (36/148) of the patients given benzylpenicillin plus an aminoglycoside, compared with 52% (95% CI 44%-60%), (78/149) of the patients given meropenem, had no modifications of their regimens (p0.001). In the benzylpenicillin plus an aminoglycoside arm, the all-cause fatality within 30 days of randomization was 3.4% (95% CI 1.2%-7.9%), (5/148) of the patients, compared with 0% (95% CI 0.0%-3.0%), (0/149) of the patients in the meropenem arm (p 0.03).Clinical success was more common in FN patients randomized to meropenem compared with the patients randomized to benzylpenicillin plus an aminoglycoside. The all-cause fatality was higher among the patients given benzylpenicillin plus an aminoglycoside. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|